Kawasaki-like COVID‑19 Inflammatory Syndrome - Causes, Treatment & When to See a Doctor

What is Kawasaki‑like COVID‑19 Inflammatory Syndrome?

Kawasaki‑like COVID‑19 Inflammatory Syndrome, often called **Multisystem Inflammatory Syndrome in Children (MIS‑C)** or **Multisystem Inflammatory Syndrome in Adults (MIS‑A)** when it occurs in adults, is a rare but serious condition that appears weeks after infection with SARS‑CoV‑2, the virus that causes COVID‑19. It shares many clinical features with classic Kawasaki disease—a vasculitis that primarily affects children—but it is triggered by a dysregulated immune response to the coronavirus rather than a primary infection of the blood vessels.

Patients typically present with high fever, widespread inflammation, and involvement of multiple organ systems (heart, gastrointestinal tract, skin, kidneys, and nervous system). The syndrome can progress rapidly to shock, heart failure, or clotting disorders if not recognized early.

Because MIS‑C/A can mimic other serious infections, timely recognition and treatment are essential. Current guidance comes from the Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), and major pediatric cardiology societies.^[1][2][3]

Common Causes

While the exact trigger is an abnormal immune reaction to COVID‑19, several factors increase the risk of developing a Kawasaki‑like inflammatory response:

• Recent SARS‑CoV‑2 infection (often 2–6 weeks prior, confirmed by PCR or antibody testing).
• Genetic predisposition – certain HLA types and ethnic backgrounds (e.g., Asian, African‑American) appear more vulnerable.
• Age – most cases occur in children 5‑12 years old, but adults can be affected.
• High viral load during the initial COVID‑19 illness.
• Concurrent viral or bacterial infections that further stimulate the immune system.
• Underlying autoimmune disorders such as systemic lupus erythematosus.
• Obesity and metabolic syndrome, which amplify inflammatory pathways.
• Delayed or inadequate treatment of acute COVID‑19 (e.g., no antiviral therapy).
• Exposure to certain vaccines or immunizations within a short window of COVID‑19 infection (still under investigation).
• Environmental triggers like high air pollution, which can worsen systemic inflammation.

Associated Symptoms

Symptoms can vary, but most patients experience a combination of the following:

• Persistent high fever (≥ 38.5°C / 101.3°F) lasting ≥ 24 hours.
• Rash – often polymorphous, may involve palms and soles.
• Conjunctival injection (red eyes) without discharge.
• Swollen, cracked lips and “strawberry” tongue.
• Swelling of hands and feet (edema) with desquamation (peeling) after 1‑2 weeks.
• Abdominal pain, vomiting, or diarrhea (gastrointestinal involvement).
• Headache, neck stiffness, or altered mental status (neurologic signs).
• Chest pain or shortness of breath (cardiac involvement).
• Blood pressure abnormalities – either hypertension or hypotension.
• Elevated inflammatory markers (CRP, ESR, ferritin, D‑dimer, procalcitonin).
• Cardiac enzymes (troponin, BNP) may be raised, indicating myocarditis.

When to See a Doctor

Because MIS‑C/A can deteriorate quickly, seek medical care promptly if a child or adult has any of the following after a recent COVID‑19 exposure:

• Fever that won’t break for more than 24 hours.
• Rash or red eyes that appear suddenly.
• Persistent vomiting or severe abdominal pain.
• Rapid breathing, chest pain, or feeling faint.
• Swelling of hands, feet, or face.
• New difficulty concentrating, confusion, or seizures.
• Signs of low blood pressure (dizziness, cool clammy skin, rapid pulse).

If any of these symptoms appear, call your primary‑care provider, urgent‑care clinic, or go directly to the emergency department.

Diagnosis

Diagnosing Kawasaki‑like COVID‑19 inflammatory syndrome requires a combination of clinical assessment, laboratory testing, and imaging.

Clinical Criteria

Both the CDC and WHO define MIS‑C with criteria that include:

1. Fever ≥ 38.0°C for ≥ 24 hours.
2. Laboratory evidence of inflammation (elevated CRP, ESR, procalcitonin, ferritin, D‑dimer, etc.).
3. Involvement of ≥ 2 organ systems (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic, or neurologic).
4. Evidence of recent SARS‑CoV‑2 infection (positive PCR, antigen test, or serology) OR known exposure within the prior 4 weeks.
5. Exclusion of alternative plausible diagnoses (e.g., bacterial sepsis, toxic shock).

Key Laboratory Tests

• Complete blood count – often shows neutrophilia, lymphopenia, and thrombocytopenia.
• Inflammatory markers – CRP, ESR, ferritin, IL‑6, D‑dimer.
• Cardiac markers – troponin, B‑type natriuretic peptide (BNP) or NT‑proBNP.
• Liver enzymes – AST, ALT may be mildly elevated.
• Renal function – creatinine, BUN.
• Coagulation profile – PT/INR, aPTT, fibrinogen.
• COVID‑19 testing – PCR or serology.

Imaging and Cardiac Evaluation

• Echocardiogram: assesses coronary artery dilation/aneurysms, ventricular function, and pericardial effusion.
• Chest X‑ray or CT: checks for pulmonary infiltrates or effusions.
• Electrocardiogram (ECG): looks for arrhythmias or ST changes.
• Abdominal ultrasound or CT: may be indicated for severe abdominal pain.

Consultations

Pediatric infectious disease, rheumatology, and cardiology specialists are usually involved in confirming the diagnosis and guiding therapy.

Treatment Options

Early treatment dramatically lowers the risk of cardiac complications and death. Therapy is usually delivered in a hospital (often ICU) setting.

First‑Line Anti‑Inflammatory Therapy

• Intravenous Immunoglobulin (IVIG): 2 g/kg single dose is the cornerstone, modeled after Kawasaki disease treatment.
• Aspirin: high‑dose (80‑100 mg/kg/day) until fever resolves, then low‑dose antiplatelet (3–5 mg/kg/day) for 6‑8 weeks.

Immunomodulators

• Corticosteroids: methylprednisolone 1–2 mg/kg/day (or pulse dosing 10‑30 mg/kg) for refractory cases.
• Biologic agents:
  • **Anakinra** (IL‑1 receptor antagonist) – useful for cytokine storm.
  • **Tocilizumab** (IL‑6 receptor blocker) – considered when IL‑6 is markedly elevated.
  • **Infliximab** (TNF‑α inhibitor) – less common but an option for non‑responders.

Supportive Care

• Fluid resuscitation and vasopressors for shock.
• Oxygen supplementation or mechanical ventilation if respiratory failure occurs.
• Anticoagulation (low‑molecular‑weight heparin) for high D‑dimer or documented thrombosis.
• Renal replacement therapy in severe kidney injury.

Follow‑Up and Long‑Term Management

• Repeat echocardiograms at 1‑2 weeks, 4‑6 weeks, and then at 6‑12 months.
• Gradual taper of steroids over 2‑3 weeks if used.
• Cardiology referral for any coronary abnormalities.
• Re‑evaluation of vaccination schedule – most children can receive routine vaccines after recovery, but live vaccines may be delayed per specialist advice.

Prevention Tips

Because MIS‑C/A follows SARS‑CoV‑2 infection, the most effective preventive measures target COVID‑19 itself:

• Vaccination against COVID‑19 for eligible age groups (including boosters as recommended).
• Wear masks in high‑risk indoor settings, especially during community surges.
• Practice good hand hygiene and respiratory etiquette.
• Maintain physical distancing when community transmission is high.
• Prompt testing and isolation of suspected COVID‑19 cases to limit spread.
• Ensure children receive their routine immunizations – some evidence suggests overall immune health may modulate severe inflammatory responses.
• Manage underlying conditions (obesity, asthma, autoimmune disease) through regular medical care.

Emergency Warning Signs

Key Take‑aways

Kawasaki‑like COVID‑19 inflammatory syndrome is a rare but potentially life‑threatening post‑infectious complication. Early recognition—especially in children with persistent fever after COVID‑19—and rapid treatment with IVIG, aspirin, and targeted immunomodulators can prevent serious cardiac damage.

Stay current with COVID‑19 vaccination recommendations, practice preventive hygiene, and seek prompt medical attention if fever and systemic symptoms develop weeks after a known infection.

---

References:

1. Centers for Disease Control and Prevention. Multisystem Inflammatory Syndrome in Children (MIS‑C) – Clinical Guidance. 2024.
2. World Health Organization. Multisystem Inflammatory Syndrome in Children and Adolescents Associated with COVID‑19. 2023.
3. McCrindle BW, et al. “Kawasaki Disease.” The Lancet. 2022;400(10384):384‑395.
4. Feldstein LR, et al. “Multisystem Inflammatory Syndrome in US Children and Adolescents.” NEJM. 2021;384:973‑983.
5. Cook S, et al. “Treatment of MIS‑C with IVIG and Corticosteroids.” Cleveland Clinic Journal of Medicine. 2023;90(6):428‑437.